ACTIVITY OF A NEW TRIAZOLE, SCH 56592, COMPARED WITH THOSE OF 4 OTHERANTIFUNGAL AGENTS TESTED AGAINST CLINICAL ISOLATES OF CANDIDA SPP ANDSACCHAROMYCES-CEREVISIAE

Sch 56592 is a new triazole agent with potent, broad-spectrum antifung al activity, The in vitro activities of Sch 56592, itraconazole, fluco nazole, amphotericin B, and flucytosine (5-FC) against 404 clinical is olates of Candida spp, (382 isolates) and Saccharomyces cerevisiae (22 isolates) were investigated, In vitro susceptibility testing was perf ormed by a broth microdilution method performed according to National Committee for Clinical Laboratory Standards guidelines, Overall, Sch 5 6592 was very active (MIG at which 90% of isolates are inhibited [MIC( 90)], 0.5 mu g/ml) against these yeast isolates, Sch 56592 was most ac tive against Candida tropicalis, Candida parapsilosis, Candida lusitan iae, and Candida stellatoidea (MIC(90), less than or equal to 0.12 mu g/ml) and was least active against Candida glabrata (MIC(90), 2.0 mu g /ml). Sch 56592 was 2- to 32-fold more active than amphotericin B and 5-FC against all species except C. glabrata, By comparison,vith the ot her triazoles, Sch 56592 was equivalent to itraconazole and greater th an or equal to eightfold more active than fluconazole. On the basis of these results, Sch 56592 has promising antifungal activity, and furth er in vitro and in vivo investigations are warranted.